October 9, 2023 12:58 PM EDT
Pharma
Manufacturing

Bio­con’s in­sulin biosim­i­lar re­ject­ed yet again by FDA af­ter man­u­fac­tur­ing de­fi­cien­cies

Ayisha Sharma

News Reporter

The FDA has re­ject­ed Bio­con Bi­o­log­ics’ biosim­i­lar ver­sion of in­sulin as­part due to is­sues iden­ti­fied at its Malaysia fa­cil­i­ty af­ter an Aug. 2022 in­spec­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times